When drugmaker Cadila Healthcare introduces its ZyCoV-D product next month, all Indian youngsters aged 12 and above will be eligible for COVID-19 vaccines, according to two individuals with firsthand knowledge of the situation.
Last month, Indian regulators granted emergency approval to ZyCoV-D, the world’s first DNA-based COVID-19 vaccine. The business, commonly known as Zydus Cadila, will begin producing 10 million pills each month in October.
In India, the vaccine is the only one licenced for children, with adults receiving 825.9 million doses out of a population of roughly 1.4 billion.
ZyCoV-D is a three-dose vaccination that will be given on the first day, the 28th day, and the 56th day.
It’s a needle-free vaccination that’s delivered through The Pharma Jet, a needle-free applicator called Tropis that enables painless intradermal vaccine administration.
